SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

11/12/24 10:34:14 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $TEVA alert in real time by email

SC 13G 1 filing.txt SCHEDULE 13G Amendment No.0 TEVA PHARMACEUTICAL INDS LTD COMMON STOCK Cusip #M8769Q102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #M8769Q102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 62,301,623 Item 6: 0 Item 7: 62,740,762 Item 8: 0 Item 9: 62,740,762 Item 11: 5.537% Item 12: HC Cusip #M8769Q102 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 62,740,762 Item 8: 0 Item 9: 62,740,762 Item 11: 5.537% Item 12: IN Item 1(a). Name of Issuer: TEVA PHARMACEUTICAL INDS LTD Item 1(b). Address of Issuer's Principal Executive Offices: 5 Bazel St, POB 3190 Petach, Tikva 49131 Israel Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: M8769Q102 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 62,740,762 (b) Percent of Class: 5.537% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 62,740,762 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of TEVA PHARMACEUTICAL INDS LTD. No one other person's interest in the COMMON STOCK of TEVA PHARMACEUTICAL INDS LTD is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification FIAM LLC IA Fidelity Institutional Asset Management Trust Company BK Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Strategic Advisers LLC IA Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of TEVA PHARMACEUTICAL INDS LTD at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $TEVA alert in real time by email

Recent Analyst Ratings for

$TEVA

Date	Price Target	Rating	Analyst
7/10/2024	$20.00	Hold → Buy	Argus
3/8/2024	$14.00	Underweight → Neutral	JP Morgan
2/12/2024	$12.00 → $19.00	Neutral → Overweight	Piper Sandler
1/23/2024	$10.00 → $14.00	Hold → Buy	Jefferies
1/3/2024	$8.00 → $12.00	Underweight → Neutral	Piper Sandler
12/18/2023	$13.00	Buy	HSBC Securities
11/27/2023	$11.00 → $13.00	Neutral → Buy	UBS
7/6/2023	$7.00 → $8.00	Sell → Neutral	UBS

More analyst ratings

SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

Chat with this insight

Recent Analyst Ratings for $TEVA

$TEVA Press Releases

Fastest customizable press release news feed in the world

Teva to Present at the Jefferies London Healthcare Conference

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition

$TEVA Leadership Updates

Live Leadership Updates

Teva Announces Appointment of Matthew Shields to Executive Vice President, Teva Global Operations

Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business

Teva Announces Changes to Executive Management Team

$TEVA Financials

Live finance-specific insights

Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS

Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024

Teva Announces Strong Growth in Second Quarter Revenues mainly driven by Generics Products in All Regions and AUSTEDO®; Raises 2024 Financial Guidance

$TEVA Market Insights

Live Market Insights

Teva And Sanofi Fast-Track Anti-TL1A Phase 2b Trial For Inflammatory Bowel Disease

Why Hims & Hers Heath Shares Are Surging Today

$100 Invested In This Stock 5 Years Ago Would Be Worth $200 Today

$TEVA Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Teva Pharma upgraded by Argus with a new price target

Teva Pharma upgraded by JP Morgan with a new price target

Teva Pharma upgraded by Piper Sandler with a new price target

$TEVA SEC Filings

SEC Form 8-K filed by Teva Pharmaceutical Industries Limited

SEC Form 10-Q filed by Teva Pharmaceutical Industries Limited

Teva Pharmaceutical Industries Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$TEVA Large Ownership Changes

This live feed shows all institutional transactions in real time.

SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

SEC Form SC 13G/A filed by Teva Pharmaceutical Industries Limited (Amendment)

SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

$TEVA Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Shalev Varda converted options into 12,872 units of Ordinary Shares (SEC Form 4)

Exec. VP, European Commercial Daniell Richard sold $1,711,447 worth of Ordinary Shares (98,943 units at $17.30), closing all direct ownership in the company (SEC Form 4)

EVP, Business Development Grant Angus converted options into 12,913 units of Ordinary Shares and sold $70,243 worth of Ordinary Shares (4,065 units at $17.28) (SEC Form 4)

Recent Analyst Ratings for
$TEVA

$TEVA
Press Releases

$TEVA
Leadership Updates

$TEVA
Financials

$TEVA
Market Insights

$TEVA
Analyst Ratings

$TEVA
SEC Filings

$TEVA
Large Ownership Changes

$TEVA
Insider Trading